← Back to Search

Monoclonal Antibodies

secukinumab for Plaque Psoriasis (ARROW Trial)

Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 week
Awards & highlights
No Placebo-Only Group

Summary

The aim of this study was to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic plaques that remain active despite treatment with the non-selective IL-23 inhibitor ustekinumab (blocker of p40 subunit, shared by IL-12 and IL 23).

Eligible Conditions
  • Plaque Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of Subjects Whose Plaque Achieves "Clear" or "Almost Clear" Status (TCS = 0-2)

Side effects data

From 2020 Phase 2 trial • 40 Patients • NCT03553823
10%
Gout
10%
Nasopharyngitis
5%
Acute kidney injury
5%
Asthma
5%
Gastritis
5%
Pneumonia
5%
Sepsis
5%
Blood bilirubin increased
5%
Dacryostenosis acquired
5%
Erysipelas
5%
Herpes zoster
5%
Hyperglycaemia
5%
Postoperative wound infection
5%
Vulvovaginal mycotic infection
5%
Wound dehiscence
5%
Balanoposthitis
5%
Miliaria
100%
80%
60%
40%
20%
0%
Study treatment Arm
Secukinumab
Guselkumab

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: secukinumabExperimental Treatment1 Intervention
20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
Group II: GuselkumabActive Control1 Intervention
20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Skin biopsies
2012
Completed Phase 2
~590

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,913 Previous Clinical Trials
4,253,123 Total Patients Enrolled
~6 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top